Endocrine Carcinoma — Trials

Endocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 574
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +1.5%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (236)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05403723	Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC	suspended	Phase 1	50	University of Maryland, BaltimoreOTHER	1	Sep 14, 2026	clinicaltrials
NCT03392064	A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC	suspended	Phase 1	6	AmgenINDUSTRY	1	Oct 15, 2025	clinicaltrials